MedTrace Logo

MRSA Decolonization in Complicated Carriage

NCT05268120 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2025-03-06

No results posted yet for this study

Summary

Multicenter open-label cluster randomized controlled trial determining the superiority of doxycycline-rifampicin compared to trimethoprim-rifampicin for the decolonization treatment of complicated MRSA carriership.

Conditions

  • MRSA

Interventions

DRUG

doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.

Both first choice treatments in Dutch guideline for MRSA decolonization

DRUG

trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.

Both first choice treatments in Dutch guideline for MRSA decolonization

Sponsors & Collaborators

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • Merel Lambregts, MD PhD · Leiden University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2028-05-01
Completion
2028-05-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05268120 on ClinicalTrials.gov